KEYNOTE-091

NCT02504372 📎

Regimen

Experimental
pembrolizumab adjuvant
Control
placebo

Population

Resected stage IB-IIIA NSCLC post adjuvant chemo

Key finding

Overall DFS HR 0.76 (0.63-0.91); PD-L1≥50% DFS HR 0.82 (NS); positive overall population

Source: PMID 36108662

Timeline

  • Enrollment start: 2015-11-06 📎

Guideline citations

  • NCCN NSCLC Version 5.2026 (p.94)
  • CSCO NSCLC 2025 ⚠️ OCR source